Results 171 to 180 of about 92,044 (339)

Organ‐sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision‐making

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumor types and confers a characteristic microsatellite instability‐high (MSI‐H) molecular phenotype. The MSI‐H/dMMR phenotype may arise from an inherited pathogenic variant in the context of Lynch syndrome and is most frequently observed in ...
Martin Duval   +8 more
wiley   +1 more source

Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next? [PDF]

open access: yes, 2019
Cripe, James C   +8 more
core   +1 more source

Cancer pattern in Bhutan (2014–2022): Findings from population‐based cancer registry—A pathway to monitor cancer control activities

open access: yesInternational Journal of Cancer, EarlyView.
What's New? The establishment in 2014 of the population‐based cancer registry (PBCR) of Bhutan created new opportunities for understanding national cancer trends, which previously were anticipated from data in neighbouring countries. This study presents the first nine‐year summary of cancer patterns in Bhutan, derived from PBCR data. From 2014 to 2022,
Phub Tshering   +9 more
wiley   +1 more source

Role of Minimally Invasive Surgery in Gynecologic Oncology

open access: green, 2015
Lesley B. Conrad   +6 more
openalex   +2 more sources

Patient‐ and caregiver‐reported barriers to chemotherapy in nine sub‐Saharan African countries: A cross‐sectional survey among population‐based registries

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Increasing cancer incidence and mortality in low‐ and middle‐income countries has heightened concerns about limited resources and barriers to care. This challenge is particularly urgent in Sub‐Saharan Africa (SSA), where cancer rates are rising sharply. Here, data from population‐based cancer registries in nine SSA countries was assessed to
Tamara König   +19 more
wiley   +1 more source

A Phase 2 Evaluation of Irofulven as Second-line Treatment of Recurrent or Persistent Intermediately Platinum-Sensitive Ovarian or Primary Peritoneal Cancer A Gynecologic Oncology Group Trial

open access: green, 2010
Russell J. Schilder   +8 more
openalex   +2 more sources

Pubertal timing and incident uterine cancer in the Sister Study cohort

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Younger age at menarche is an established risk factor for uterine cancer. Age at onset of breast development (thelarche), the earliest marker of pubertal estrogen exposure unopposed by progesterone, may also be relevant to uterine cancer risk, but this association has not been explored. Using data from the US prospective Sister Study cohort,
Ariayana N. Harrell   +4 more
wiley   +1 more source

Evaluation of a Quality-Improvement Initiative to Address Nutritional Anemia in Gynecologic Oncology. [PDF]

open access: yesO G Open
Foley OW   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy